Stijn aims to develop PROteolysis Targeting Chimeras (PROTACs), a novel class of drugs able to induce protein degradation, for the treatment of neuroblastoma. As opposed to conventional small molecule inhibitors, which solely inhibit the catalytic function of proteins, PROTACs can induce the degradation of proteins. In the Molenaar group several oncogenic drivers in neuroblastoma have been identified, some of which are considered ‘undruggable’ using conventional small molecule inhibitors. This project attempts to use PROTACs to selectively degrade the ‘undruggable’ neuroblastoma-associated proteins as a next generation therapeutic strategy for neuroblastoma.
Contactgegevens
Email: S.T.Couwenbergh-2@prinsesmaximacentrum.nl